Migraine management: Current trends and future prospects;Actualités thérapeutiques dans la migraine

Revue Medicale de Liege

Volumn 63, Issue 5-6, 2008, Pages 315-329

  Fumal, A ^a   Gerardy P Y ^a   Schoenen, J ^a  

^a Centre Hospitalier Regional de La Citadelle   (Belgium)

Author keywords

Acute treatment; Disability; Management; Migraine; Preventive treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMITRIPTYLINE; AMYLOCAINE; ANALGESIC AGENT; BISOPROLOL; CAFFEINE; CLOMIPRAMINE; DICLOFENAC; DIPYRONE; DOMPERIDONE; ERGOTAMINE; FLUNARIZINE; IBUPROFEN; INDOMETACIN; METHYSERGIDE; METOCLOPRAMIDE; METOPROLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENAZONE; PROPRANOLOL; RIBOFLAVIN; STEROID; SUMATRIPTAN; TOLFENAMIC ACID; TOPIRAMATE; TRIPTAN DERIVATIVE; UBIDECARENONE; UNINDEXED DRUG; VALPROIC ACID;

ALGORITHM; CLINICAL FEATURE; CLINICAL PRACTICE; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DISABILITY; FATIGUE; HUMAN; LIVER TOXICITY; MIGRAINE; MUSCLE CRAMP; NAUSEA; PARESTHESIA; PARKINSONISM; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RETROPERITONEAL FIBROSIS; REVIEW; SOMNOLENCE; TERATOGENICITY; VERTIGO;

ALGORITHMS; FORECASTING; HUMANS; MIGRAINE DISORDERS; PHENOTYPE;

EID: 47249104401     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Leonardi M, Steiner TJ, Scher AT, et al. - The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain, 2005, 6, 429-440.
2. Andlin-Sobocki P, Jönsson B, Wittchen HU, et al. - Cost of disorders of the brain in Europe. Eur J Neurol, 2005,12, 1-27.
3. Berg J, Stovner LJ. - Cost of migraine and other headaches in Europe. Eur J Neurol, 2005, 12, 59-62.
4. Clouse JC, Osterhaus JT. - Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother, 1994, 28, 659-664.
5. Hu XH, Markson LE, Lipton RB, et al. - Burden of migraine in the United States: disability and economic costs. Arch Intern Med, 1999, 159, 813-818.
6. Osterhaus JT, Gutterman DL, Plachetka JR. - Healthcare resource and lost labour costs of migraine headache in the US. Pharmacoeconomics, 1992, 2, 67-76.
7. Diamond S, Bigal ME, Silberstein S, et al. - Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache, 2007, 47, 355-363.
8. Steiner TJ, Scher AI, Stewart WF, et al. - The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia, 2003, 23, 519-527.
9. Lipton RB, Stewart WF, Diamond S, et al. - Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache, 2001, 41, 646-657.
10. Lipton RB, Bigal ME, Diamond M, et al. - Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 2007, 68, 343-349.
11. Patel NV, Bigal ME, Kolodner KB, et al. - Prevalence and impact of migraine and probable migraine in a health plan. Neurology, 2004, 63, 1432-1438.
12. Diener HC, Dahlof CG. - Headache associated with chronic use of substances. In: The Headaches (2nd edition). Olesen J, Tfelt-Hansen P, Welch KMA (Eds). Lippincott, Williams & Wilkins, Philadelphia, USA, 1999, 871-878.
13. Obermann M, Katsarava Z. - Management of medication-overuse headache. Expert Rev. Neurotherapeutics. 2007, 7, 1145-1155.
14. International Headache Society. - Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia, 1988, 8, 1-96.
15. The International Classification of Headache Disorders. 2nd Edition (ICHD-II). Cephalalgia, 2004, 24, 1-160.
16. Vincent MB, Hadjikhani N. - Migraine aura and related phenomena : beyond scotoma and scintillations. Cephalalgia, 2007, 27, 1368-1377.
17. Olesen J, Bousser MG, Diener HC, et al. - New appendix criteria open for a broader concept of chronic migraine. Cephalalgia, 2006, 26, 742-746.
18. Silbertsein SD, Olesen J, Bousser MG, et al. - The International Classification of Headache Disorders, 2nd edition - revision of criteria for 8.2 Medication-overuse headache. Cephalalgia, 2005, 25, 460-465.
19. Fumal A, Schoenen J. - Tension-Type headache: current research and clinical management. Lancet Neurology, 2008, 7, 70-83.
20. Rasmussen BK, Jensen R, Olesen J. - A population-based analysis of the criteria of the International Headache Society. Cephalalgia, 1991, 11, 129-134.
21. Schoenen J, Wang W. - Tension-type Headache. In : Goadsby PJ, Silberstein SJ (eds): Headache. Boston : Butterworth-Heinemann, 1997, 177-200.
22. Schoonman GG, Evers DJ, Terwindt GM, et al. - The prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients. Cephalalgia, 2006, 26, 1209-1213.
23. Karli N, Zarifoglu M, Calisir N, et al. - Comparison of pre-headache phases and trigger factors of migraine and episodic tension-type headache: do they share similar clinical pathophysiology? Cephalalgia, 2005, 25, 444-451.
24. Breslau N, Lipton RB, StewartWF, et al. - Comorbidity of migraine and depression: Investigating potential etiology and prognosis. Neurology, 2003, 60, 1308-1312.
25. Eggers SD. - Migraine-related vertigo: diagnosis and treatment. Curr Pain Headache Rep, 2007, 11, 217-226.
26. van de Ven RC, Kaja S, Plomp JJ, et al. - Genetic models of migraine. Arch Neurol, 2007, 64, 643-646.
27. Stewart WF, Staffa J, Lipton RB, et al. - Familial risk of migraine: a population-based study. Ann Neurol, 1997, 41, 166-172.
28. Haan J, Kors EE, Vanmolkot KR, van et al. - Migraine genetics: an update. Curr Pain Headache Rep, 2005, 9, 213-220.
29. Ambrosini A, Maertens de Noordhout A, Schoenen J. - Neuromuscular transmission in migraine: a single fiber EMG study in clinical subgroups. Neurology, 2001, 56, 1038-1043.
30. Sándor PS, Mascia A, Seidel L, et al. - Subclinical cerebellar impairment in the common types of migraine: A 3-dimensional analysis of reaching movements. Ann Neurol, 2001, 49, 668-672.
31. Schoenen J, Ambrosini A, Sándor PS, et al. - Evoked potentials and transcranial magnetic stimulation in migraine: published data and viewpoint on their pathophysiologic significance. Clin Neurophysiol, 2003, 114, 955-972.
32. Fumai A, Schoenen J. - Genetics of Migraines : from ionic channels to single nucleotide polymorphisms? Rev Med Liège, 2004, 59, 367-377.
33. Goadsby P. - Recent advances in the diagnosis and management of migraine. BMJ, 2006, 332, 25-29.
34. Sándor PS, Ambrosini A, Agosti R, et al. - Genetics of migraine and possible links to neurophysiological abnormalities. Pain Clinical Updates, 2001, 9, 1-4.
35. Silberstein SD, Rosenberg J. - Multispecialty consensus on diagnosis and treatment of headache. Neurology, 2000, 54, 1553.
36. Schoenen J. - The pathophysiology of migraine : a review based on the literature and on personal contributions. Functional Neurology, 1998,13, 7-15.
37. Goadsby PJ, Lipton RB, Ferrari MD. - Migraine-current understanding and treatment. N Engl J Med, 2002, 24, 257-270.
38. Moskowitz MA. - Genes, proteases, cortical spreading depression and migraine : impact on pathophysiology and treatment. Fund Neurol, 2007, 22, 133-136.
39. Goadsby PJ. - Recent advances in understanding migraine mechanisms, molecules and therapeutics. Trends Mol Med, 2007, 13, 39-44.
40. Evers S, Afra J, Frese A, et al. - EFNS guidelines on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol, 2006, 13, 560-572.
41. Nebe J, Heier M, Diener HC. - Low-dose ibuprofen in self-medication of mild to moderate headache: a comparison with acetylsalicylic acid and placebo. Cephalalgia, 1995, 15, 531-535.
42. Diener HC, Bussone G, de Liano H, et al. - Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia, 2004, 24, 947-954.
43. Di Monda V, Nicolodi M, Aloisio A, et al. - Efficacy of a fixed combination of indomethacin, prochlorperazine, and caffeine versus sumatriptan in acute treatment of multiple migraine attacks: a multicenter, randomized, crossover trial. Headache, 2003, 43, 835-844.
44. Diener H, Pfaffenrath V, Pageler L. - The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia, 2005, 25, 776-787.
45. Goldstein J, Silberstein SD, Saper JR, et al. - Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache, 2006, 46, 444-453.
46. Evers S, Gralow I, Bauer B, et al. - Sumatriptan and ergotamine overuse and drug-induced headache : a clinicoepidemiologic study. Clin Neuropharmacol, 1999, 22, 201-206.
47. Tfelt-Hansen P, Saxena PR, Dahlof C, et al. - Ergotamine in the acute treatment of migraine: a review and European consensus. Brain, 2000, 123, 9-18.
48. Colman I, Brown MD, Innes GD, et al. - Parenteral dihydroergotamine for acute migraine headache : a systematic review of the literature. Ann Emerg Med, 2005, 45, 393-401.
49. Boureau F, Kappos L, Schoenen J, et al. - A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int J Clin Pract, 2000, 54, 281-286.
50. Humphrey PPA, Goadsby PJ. - The mode of action of sumatriptan is vascular? A debate. Cephalalgia, 1994, 14, 401-410.
51. Ferrarri MD, Roon KI, Lipton RB, et al. - Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet, 2001, 358, 1668-1675.
52. Dodick D, Lipton RB, Martin V, et al. - Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache, 2004, 44, 414-425.
53. Schoenen J, Bulcke J, Caekebeke J, et al. - Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device : comparison with customary treatment in an open, longitudinal study. Cephalalgia, 1994, 14, 55-63.
54. Diener HC, for the ASASUMAMIG Study Group. - Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. Cephalalgia, 1999, 19, 581-588.
55. Brandes JL, Kudrow D, Stark SR, et al. - Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA, 2007, 297, 1443-1454.
56. Schoenen J, De Klippel N, Giurgea S, et al. - Almotriptan and its combination with aceclofenac for migraine attacks : a study of efficacy and the influence of auto-evaluated brush allodynia. Cephalalgia, 2008 (sous presse).
57. Davies GM, Santanello N, Lipton R. - Determinants of patient satisfaction with migraine therapy. Cephalalgia, 2000, 20, 554-560.
58. Pradel FG, Subedi P, Varghese AA, et al. - Does earlier headache response equate to earlier return to functioning in patients suffering from migraine? Cephalalgia, 2006, 26, 428-435.
59. Schoenen J, Jacquy J, Lenaerts M. - Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology, 1998, 50, 466-470.
60. Sándor PS, Di Clemente L, Coppola G, et al. - Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology, 2005, 64, 713-715.
61. Schrader H, Stovner LJ, Heide G, et al. - Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ, 2001, 322, 19-22.
62. Tronvik E, Stovner LJ, Heide G, et al. - Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomised controlled trial. JAMA, 2003, 289, 65-69.
63. Peikert A, Wilimzig C, Könne-Volland R. - Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia, 1996, 16, 257-263.
64. Diener HC, Rahlfs VW, Danesch U. - The first placebo controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. European Neurology, 2004, 51, 89-97.
65. Lipton RB, Göbel H, Einhaupl KM, et al. - Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology, 2004, 63, 2240-2244.
66. Diener HC, Pfaffenrath V, Schnitker J, et al. - Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention- a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia, 2005, 25, 1031-41.
67. Schoenen J, Di Clemente L, Coppola G. - Other prophylactic anti-migraine agents: riboflavin, feverfew, magnesium, Botulinum toxin, and calcium antagonists. In : Preventive Pharmacotherapy of Headache Disorders. Jes Olesen, Stephen D. Silberstein, Peer Tfelt-Hansen (editors), Oxford, University Press, 2004, 121-133.
68. Tfelt-Hansen P, Block G, Dahlöf C, et al. - Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia, 2000, 20, 765-786.
69. Peres MF, Silberstein S, Moreira F, et al. - Patients' preference for migraine preventive therapy. Headache, 2007, 47, 540-545.
70. Bendtsen L. - Amitriptyline in the treatment of primary headaches. Expert Review of Neurotherapeutics, 2003, 3, 165-173.
71. Silberstein SD for the US Headache Consortium. - Practice parameter: Evidence Based guidelines for migraine headache (an Evidence-based review). Neurology, 2000, 55, 754-762.
72. D'Andrea G, Granella F, Cadaldini M, et al. - Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia, 1999, 19, 64-66.
73. Lampl C, Katsarava Z, Diener HC, et al. - Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry, 2005, 76, 1730-1732.
74. Steiner TJ, Findley LJ, Yuen AW. - Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia, 1997, 17, 109-112.
75. Gupta P, Singh S, Goyal V, et al. - Low-dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache, 2007, 47, 402-412.
76. Schoenen J. - Future preventive therapy : are there promising drug targets? Headache Currents, 2006, 3, 108-111.
77. Silberstein SD, Stark SR, Lucas SM, et al. - Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebocontrolled trial. Mayo Clin Proc, 2005, 80, 1126-1137.
78. Mathew NT, Frishberg BM, Gawel M, et al. - Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache, 2005, 45, 293-307.
79. Relja M, Poole AC, Schoenen J, et al. - A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia, 2007, 27, 492- 503.
80. Delstanche S, Schoenen J. - La toxine botulinique dans le traitement des céphalées. Neurone, 2006, 11, 148-154.
81. Nestoriuc Y, Martin A. - Efficacy of biofeedback for migraine: A meta-analysis. Pain, 2007, 128, 111-127.
82. Trautmann E, Lackschewitz H, Kröner-Herwig B. - Psychological treatment of recurrent headache in children and adolescents - a meta-analysis. Cephalalgia, 2006, 26, 1411-1426.
83. Witt CM, Reinhold T, Jena S, et al. - Cost-effectiveness of acupuncture treatment in patients with headache. Cephalalgia, 2008, 28, 334-345.
84. Facco E, Liguori A, Petti F, et al. - Traditional Acupuncture in Migraine : A Controlled, Randomized Study. Headache, 2008, 48, 398-407.
85. Streng A, Linde K, Hoppe A, et al. - Effectiveness and tolerability of acupuncture compared with metoprolol in migraine prophylaxis. Headache, 2006, 46, 1492-1502.
86. Diener HC, Kronfeld K, Boewing G, et al. - Efficacy of acupuncture for the prophylaxis of migraine: a multicentre randomised controlled clinical trial. Lancet Neurol, 2006, 5, 310-316.
87. Linde K, Streng A, Jürgens S, et al. - Acupuncture for patients with migraine: a randomized controlled trial. JAMA, 2005, 293, 2118-2125.
88. MacGregor A. - Menstrual migraine: a review. J Fam Plann Reprod Health Care, 2007, 33, 36-47.
89. Sargent J, Solbach P, Damasio H, et al. - A comparison of naproxen sodium to propranolol hydrochloride and a placebo control for the prophylaxis of migraine headache. Headache, 1985, 25, 320-324.
90. Facchinetti F, Fioroni L, Sances G, et al. - Naproxen sodium in the treatment of premenstrual symptoms: a placebo-controlled study. Gynecol Obstet Invest, 1989, 28, 205-208.
91. Szekely B, Meeryman S, Post G. - Prophylactic effects of naproxen sodium on perimenstrual headache: a double-blind, placebo-controlled study. Cephalalgia, 1989, 9, 452-453.
92. Nattero G, Allais G, De Lorenzo C, et al. - Biological and clinical effects of naproxen sodium in patients with menstrual migraine. Cephalalgia, 1991, 11, 201-202.
93. Newman L, Mannix LK, Landy S, et al. - Naratriptan as short-term prophylaxis in menstrually associated migraine: a randomised, double-blind, placebo-controlled study. Headache, 2001, 41, 248-256.
94. Silberstein SD, Elkind AH, Schreiber C, et al. - A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology, 2004, 63, 261-269.
95. De Lignieres B, Mauvais-Javis P, Mas JML, et al. - Prevention of menstrual migraine by percutaneous oestradiol. BMJ, 1986, 293, 1540.
96. Smits MG, van den Meer YG, Pfeil JPJM, et al. - Perimenstrual migraine: effect of Estraderm_ TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache, 1994, 34, 103-106.
97. Schoenen J. - Are migraine and headache associated with an increased risk of stroke in women? Nature Clinical Practice Neurology, 2006, 2, 74-75.
98. Schoenen J, Burette P, Materne P. - Patent foramen ovale and migraine, a fortuitus association or a causal relationship? Rev Med Liege, 2006, 61, 362-368.
99. MacGregor A. - Migraine in pregnancy and lactation : a clinical review. J Fam Plann Reprod Health Care, 2007, 33, 83-93.
100. Evers S, Pothmann R, Uberall M, et al. - Treatment of idiopathic headache in childhood - recommendations of the German Migraine and Headache Society (DMKG). Schmerz, 2002, 16, 48-56.
101. Winner P, Rothner AD, Saper J, et al. - A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics, 2000, 106, 989-997.
102. Lewis D, Ashwal S, Hershey A, et al. - American Academy of Neurology Quality Standards Subcommittee; Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology, 2004, 63, 2215-2224.
103. Evers S. - Drug treatment of migraine in children. A comparative review. Paediatric drugs, 1999, 1, 7-18.
104. Krymchantowski AV, Barbosa JS. - Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia, 2000, 20, 107-113.
105. Smith TR. - Low-dose tizanidine with nonsteroidal antiinflammatory drugs for detoxification from analgesic rebound headache. Headache, 2002, 42, 175-177.
106. Lenarduzzi P, Schoenen J, Sianard-Gainko J. - Efficacy of clomipramine during the weaning period in drug abuse headaches : a blinded study. New Trends Clin Neuropharmacol, 1988, 2, 162.
107. Raskin NH. - Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology, 1986, 36, 995-997.
108. Pageler L, Katsarava Z, Diener HC, et al. - Prednisone vs. placebo in withdrawal therapy following medication overuse headache. Cephalalgia, 2008, 28, 152-156.
109. Goldstein DJ, Roon KI, Offen WW, et al. - Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet, 2001, 358, 1230-1234.
110. Olesen J, Diener HC, Husstedt IW, et al. - Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med, 2004, 350, 1104-1110.
111. Ho TW, Mannix LK, Fan X, et al. - Randomized controlled trial of an oral CGRP antagonist, MK-0974, in acute treatment of migraine. Neurology (sous presse).
112. Lassen LH, Ashina M, Christiansen I, et al. - Nitric oxide synthase inhibition in migraine. Lancet, 1997, 349, 401-402.
113. Goadsby PJ. - Emerging therapies for migraine. Nat Clin Pract Neurol, 2007, 3, 610-619.
114. Sang CN, Ramadan NM, Wallihan RG, et al. - LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well tolerated in acute migraine. Cephalalgia, 2004, 24, 596-602.
115. NCT00269022 [http://www.clinicaltrials.gov/ct/show/NCT00269022?order=1]
116. Ayata C, Jin H, Kudo C, et al. - Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol, 2006, 59, 652-661.
117. Goadsby PJ, Ferrari MD, Olesen J, et al. - Double-blind placebo-controlled trial of tonabersat in the preventive management of migraine. Cephalalgia, 2007, 27, 1195-1196.
118. Cammarata D, Krusz JC. - Memantine : Novel mechanism for migraine and headache prophylaxis. Headache, 2005, 45, 820.
119. Spengos K, Theleritis C, Paparrigopoulos T. - Memantine and NMDA antagonism for chronic migraine : a potentially novel therapeutic approach? Headache, 2008, 48, 284-286.
120. Peeters M, Gunthorpe MJ, Strijbos PJ, et al. - Effects of pan- and subtype-selective N-methyl-D-aspartate receptor antagonists on cortical spreading depression in the rat: Therapeutic potential for migraine. J Pharmacol Exp Ther, 2007, 321, 564-572.
121. Matharu MS, Bartsch T, Ward N, et al. - Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain, 2004, 127, 220-230.
122. Burns B, Watkins L, Goadsby PJ. - Treatment of medically intractable cluster headache by occipital nerve stimulation: long-term follow-up of eight patients. Lancet, 2007, 369, 1099-1106.
123. Magis D, Allena M, Bolla M, et al. Occipital nerve stimulation for drug-resistant chronic cluster headache: a prospective pilot study. Lancet Neurol, 2007, 6, 314-321.
124. Sadler RM, Purdy RA, Rahey S. - Vagal nerve stimulation aborts migraine in patient with intractable epilepsy. Cephalalgia, 2002, 22, 482-484.
125. Mauskop A. - Vagus nerve stimulation relieves chronic refractory migraine and cluster headaches. Cephalalgia, 2005, 25, 82-86.
126. Dowson A, Mullen MJ, Peatfield R, et al. - Migraine Intervention With STARFlex Technology (MIST) trial : a prospective, multicenter, double-blind, sham-controlled trial to evaluate the effectiveness of patent foramen ovale closure with STARFlex septal repair implant to resolve refractory migraine headache. Circulation, 2008, 117, 1397-1404.